A novel therapeutic management for diabetes patients with chronic limb-threatening ischemia: comparison of autologous bone marrow mononuclear cells versus allogenic Wharton jelly-derived mesenchymal stem cells

[1]  M. Soleimani,et al.  Emerging roles of mesenchymal stem cell therapy in patients with critical limb ischemia , 2022, Stem Cell Research & Therapy.

[2]  F. Sipos,et al.  Mesenchymal Stem Cell-Derived Secretome: A Potential Therapeutic Option for Autoimmune and Immune-Mediated Inflammatory Diseases , 2022, Cells.

[3]  D. Endrei,et al.  Epidemiology of Peripheral Artery Disease: Narrative Review , 2022, Life.

[4]  A. Al-Hendy,et al.  Stem Cell Therapy: From Idea to Clinical Practice , 2022, International journal of molecular sciences.

[5]  F. Simon,et al.  Gene Therapy of Chronic Limb-Threatening Ischemia: Vascular Medical Perspectives , 2022, Journal of clinical medicine.

[6]  M. Verhaar,et al.  Human Bone Marrow Mononuclear Cells Do Not Improve Limb Perfusion in the Hindlimb Ischemia Model , 2022, Stem cells and development.

[7]  W. Koh,et al.  Diabetes and other vascular risk factors in association with the risk of lower extremity amputation in chronic limb-threatening ischemia: a prospective cohort study , 2022, Cardiovascular Diabetology.

[8]  Xiancheng Wang,et al.  The safety and efficacy of mesenchymal stem cell therapy in diabetic lower extremity vascular disease: a meta-analysis and systematic review. , 2021, Cytotherapy.

[9]  A. Magenta,et al.  Autologous cell therapy in diabetes‑associated critical limb ischemia: From basic studies to clinical outcomes (Review). , 2021, International journal of molecular medicine.

[10]  J. Laffey,et al.  Intra-vital imaging of mesenchymal stromal cell kinetics in the pulmonary vasculature during infection , 2021, Scientific Reports.

[11]  M. Durán-Ruiz,et al.  Current Status of Angiogenic Cell Therapy and Related Strategies Applied in Critical Limb Ischemia , 2021, International journal of molecular sciences.

[12]  É. B. Rangel,et al.  Mesenchymal Stem Cell Therapy for Diabetic Kidney Disease: A Review of the Studies Using Syngeneic, Autologous, Allogeneic, and Xenogeneic Cells , 2020, Stem cells international.

[13]  S. Walsh,et al.  Autologous bone marrow mesenchymal stromal cell therapy for "no-option" critical limb ischemia is limited by karyotype abnormalities. , 2020, Cytotherapy.

[14]  E. Sokal,et al.  Thrombogenic Risk Induced by Intravascular Mesenchymal Stem Cell Therapy: Current Status and Future Perspectives , 2019, Cells.

[15]  J. Xia,et al.  Stem cell secretome as a new booster for regenerative medicine. , 2019, Bioscience trends.

[16]  Yin Cao,et al.  Long-Term Outcomes of BMMSC Compared with BMMNC for Treatment of Critical Limb Ischemia and Foot Ulcer in Patients with Diabetes , 2019, Cell transplantation.

[17]  V. Capilla-González,et al.  PDGF Restores the Defective Phenotype of Adipose-Derived Mesenchymal Stromal Cells from Diabetic Patients. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  N. Lai,et al.  Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. , 2018, The Cochrane database of systematic reviews.

[19]  M. Verhaar,et al.  Cell Therapy for Chronic Limb‐Threatening Ischemia: Current Evidence and Future Directions , 2018, Stem cells translational medicine.

[20]  M. Verhaar,et al.  Mesenchymal Stromal Cell Characteristics and Regenerative Potential in Cardiovascular Disease , 2018, Cell transplantation.

[21]  D. Armstrong,et al.  Efficacy and long-term longitudinal follow-up of bone marrow mesenchymal cell transplantation therapy in a diabetic patient with recurrent lower limb bullosis diabeticorum , 2018, Stem Cell Research & Therapy.

[22]  M. Schermerhorn,et al.  Outcomes after first-time lower extremity revascularization for chronic limb-threatening ischemia in insulin-dependent diabetic patients. , 2018, Journal of vascular surgery.

[23]  G. D. de Borst,et al.  Rationale and design of the SAIL trial for intramuscular injection of allogeneic mesenchymal stromal cells in no-option critical limb ischemia. , 2017, Journal of vascular surgery.

[24]  Lei Zhou,et al.  Thromboembolism Induced by Umbilical Cord Mesenchymal Stem Cell Infusion: A Report of Two Cases and Literature Review. , 2017, Transplantation proceedings.

[25]  R. Perez-Fernandez,et al.  Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine , 2017, International journal of molecular sciences.

[26]  Shi-You Chen,et al.  Function and Therapeutic Potential of Mesenchymal Stem Cells in Atherosclerosis , 2017, Front. Cardiovasc. Med..

[27]  F. Rodier,et al.  A Proinflammatory Secretome Mediates the Impaired Immunopotency of Human Mesenchymal Stromal Cells in Elderly Patients with Atherosclerosis , 2017, Stem cells translational medicine.

[28]  N. Plesnila,et al.  The delayed addition of human mesenchymal stem cells to pre-formed endothelial cell networks results in functional vascularization of a collagen-glycosaminoglycan scaffold in vivo. , 2013, Acta biomaterialia.

[29]  B. Gauthier,et al.  Adipose Mesenchymal Stromal Cells Isolated From Type 2 Diabetic Patients Display Reduced Fibrinolytic Activity , 2013, Diabetes.

[30]  A. Caplan,et al.  MSCs: Delivery Routes and Engraftment, Cell-Targeting Strategies, and Immune Modulation , 2013, Stem cells international.

[31]  K. Kang,et al.  A phase I study of human cord blood-derived mesenchymal stem cell therapy in patients with peripheral arterial occlusive disease. , 2013, International journal of stem cells.

[32]  W. Marston,et al.  Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  J. Minguell,et al.  Vascular disease and stem cell therapies. , 2011, British medical bulletin.

[34]  Bing Chen,et al.  Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. , 2011, Diabetes research and clinical practice.

[35]  A. Zeiher,et al.  Intraarterial Administration of Bone Marrow Mononuclear Cells in Patients With Critical Limb Ischemia: A Randomized-Start, Placebo-Controlled Pilot Trial (PROVASA) , 2011, Circulation. Cardiovascular interventions.

[36]  T. Couffinhal,et al.  Hypoxia Preconditioned Mesenchymal Stem Cells Improve Vascular and Skeletal Muscle Fiber Regeneration After Ischemia Through a Wnt4-dependent Pathway. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  A. Morabito,et al.  Long-Term Prognosis of Diabetic Patients With Critical Limb Ischemia , 2009, Diabetes Care.

[38]  T. Couffinhal,et al.  Secreted Frizzled‐Related Protein‐1 Enhances Mesenchymal Stem Cell Function in Angiogenesis and Contributes to Neovessel Maturation , 2008, Stem cells.

[39]  A. Avogaro,et al.  Glucose tolerance is negatively associated with circulating progenitor cell levels , 2007, Diabetologia.

[40]  A. Avogaro,et al.  Number and Function of Endothelial Progenitor Cells as a Marker of Severity for Diabetic Vasculopathy , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[41]  Hoon Han,et al.  Successful Stem Cell Therapy Using Umbilical Cord Blood‐Derived Multipotent Stem Cells for Buerger's Disease and Ischemic Limb Disease Animal Model , 2006, Stem cells.

[42]  A. Avogaro,et al.  Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. , 2005, Journal of the American College of Cardiology.

[43]  Haruchika Masuda,et al.  Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization , 1999, Nature Medicine.

[44]  Takayuki Asahara,et al.  Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.

[45]  M. Reitz,et al.  Human mesenchymal stem cells inhibit endothelial proliferation and angiogenesis via cell-cell contact through modulation of the VE-Cadherin/β-catenin signaling pathway. , 2013, Stem cells and development.

[46]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.

[47]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[48]  O. Sangueza,et al.  A Report of Two Cases and Literature Review , 2003 .